Stockscreener 앱 받기
23.37
1.48%
0.34
시간 외 거래:
23.37
전일 마감가:
$23.03
열려 있는:
$22.84
하루 거래량:
375.90K
Relative Volume:
0.46
시가총액:
$1.25B
수익:
$10.00M
순이익/손실:
$-377.74M
주가수익비율:
-2.7678
EPS:
-8.4436
순현금흐름:
$-172.35M
1주 성능:
-4.61%
1개월 성능:
-13.51%
6개월 성능:
+23.39%
1년 성능:
+183.27%
1일 변동 폭
$22.01
$23.76
1주일 범위
$21.48
$25.97
52주 변동 폭
$6.11
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
23.37 | 1.24B | 10.00M | -377.74M | -172.35M | -8.4436 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | 개시 | Wedbush | Outperform |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
Zenas BioPharma (NASDAQ:ZBIO) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
HC Wainwright Forecasts Lower Earnings for Zenas BioPharma - MarketBeat
Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Zenas BioPharma, Inc. (ZBIO) - The Globe and Mail
Zenas BioPharma (ZBIO) Is Down 9.4% After Non-Dilutive Funding And Shelf Filing UpdateHas The Bull Case Changed? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Citigroup Issues Pessimistic Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price - MarketBeat
ZBIO: HC Wainwright & Co. Reiterates Buy Rating with $44 PT | ZB - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Receives "Buy" Rating from HC Wainwright - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Issues Quarterly Earnings Results - MarketBeat
BioPharma Credit to Invest $125 Million in Zenas BioPharma - marketscreener.com
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares - Yahoo Finance
Biopharma Credit enters senior secured loan agreement with Zenas BioPharma for up to $125 mln - marketscreener.com
Biopharma Credit Enters Senior Secured Loan Agreement With Zenas Biopharma For Up To $125 Mln - TradingView
Biopharma Credit plc Enters into Senior Secured Loan Agreement with Zenas Biopharma, Inc. for Up to Usd 125 Million - marketscreener.com
IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma - TipRanks
Zenas BioPharma (ZBIO) EPS Loss Narrows To US$2.05 Tests Growth Focused Bullish Narratives - simplywall.st
Zenas BioPharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Guggenheim raises Zenas Biopharma stock price target to $55 on pipeline progress - Investing.com Canada
New Zenas BioPharma hires receive 235,700 options, 33,450 RSUs - Stock Titan
Zenas BioPharma, Inc. ($ZBIO) Founder, CEO and COB 2025 Pay Revealed - Quiver Quantitative
Zenas BioPharma Reports 2025 Financial Results, Advances Obexelimab for IgG4-RD and SLE, Secures $250M Pharmakon Financing - Minichart
Zenas BioPharma, Inc. (ZBIO) Reports a Net Loss for Q4 FY25 - AlphaStreet
Morgan Stanley raises Zenas Biopharma stock price target on IgG4-RD outlook - Investing.com Canada
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.2%What's Next? - MarketBeat
Zenas BioPharma 2025 Annual Report: Advancing Obexelimab and I&I Therapies, Clinical Milestones, and Strategic Partnerships - Minichart
Zenas BioPharma (NASDAQ: ZBIO) plans 2026 virtual meeting, director votes - Stock Titan
Zenas BioPharma 2025 10‑K: $10.0M revenue, GAAP loss $8.44/share - TradingView
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share - marketscreener.com
Obexelimab Phase 3 success anchors Zenas BioPharma (ZBIO) immunology pipeline - Stock Titan
Zenas reports $10.0M revenue, $377.7M net loss for FY2025; cash $360.5M - TradingView
Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoYZenas BioPharma (NASDAQ:ZBIO) - Benzinga
Zenas BioPharma (Nasdaq: ZBIO) widens 2025 loss but lines up $250M Pharmakon financing - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation - ACCESS Newswire
ArrowMark Colorado Holdings LLC Reduces Stock Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Share Price Swings - Sahm
Tech Rally: Will Zenas BioPharma Inc benefit from geopolitical trendsJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Zenas Biopharma Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView
Why Is ZBIO Stock Falling Pre-Market Today? - Stocktwits
ZBIO SEC FilingsZenas BioPharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 18.8% in February - MarketBeat
The Bull Case For Zenas BioPharma (ZBIO) Could Change Following Obexelimab’s Commercial Pivot And Cash War Chest - simplywall.st
What is the target price for Zenas BioPharma Inc stockPortfolio Update Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory - Insider Monkey
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 54.59% Potential Upside Awaits Investors - DirectorsTalk Interviews
Short Covering: Will Zenas BioPharma Inc outperform during market rallies - baoquankhu1.vn
A Look At Zenas BioPharma (ZBIO) Valuation As Obexelimab Shows Strong ACTRIMS 2026 Efficacy Data - simplywall.st
ZBIOZenas BioPharma Inc. Latest Stock News & Market Updates - Stock Titan
Zenas Biopharma Inc (ZBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):